Founded in 1997, Arriva Pharmaceuticals specializes in developing anti-inflammatory therapies for respiratory diseases such as hereditary emphysema, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other respiratory indications. The company has developed technology for large-scale production of stable, non-animal sourced recombinant proteins in yeast. They have produced clinical grade recombinant alpha 1-antitrypsin (AAT) for respiratory and dermatological indications, and are working on producing maspin for the treatment of breast and prostate cancer. Arriva Pharmaceuticals aims to offer enzyme inhibitor replacement and therapy.